HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China SOEs - Waiting for Core Asset Valuation to Take Off

Fu Shou Yuan (1448.HK) - Magic Is About to Disappear, but Is Still Undervalued

Shijiazhuang Yiling Pharmaceutical (002603.CH) - Valuation Rebound Is Worth Looking Forward To

Fu Shou Yuan (1448.HK) - Some Points Worth the Attention

China Funeral Industry - Investment Opportunity with Both Alpha and Beta Superposition

Fu Shou Yuan (1448.HK)- China’s Soaring COVID-19 Death Rate Ignites High Demand for Funeral Services

Genscript Biotech (1548.HK) - Inadequate Cognition Will Lead to Bad Investment Decisions

2023 High Conviction Update: Sonoscape Medical (300633.CH) - High Growth Is Expected to Continue

Equity Bottom-Up

Fu Shou Yuan International / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/fu-shou-yuan-international" target="_blank" data-smartkarma-citation="entities:18168:1" rel="noopener">Fu Shou Yuan (1448 HK)'</a>s 2022 results were below our expectations. Affected by the 22Q4 pandemic, the performance recovery in 22H2 was lower than expected. </li>
<li>The high demand due to soaring death rate since 22Q4 would be reflected in 23H1 results. Together with low base last year, strong performance rebound in 23H1 is worth expecting.</li>
<li>The reason behind short-term trade and long-term hold is different. But considering the Company has no obvious flaws in its long logic, every pullback can be a good buying opportunity.</li>
</ul>



Fu Shou Yuan (1448 HK)'s 2022 results were below our expectations. Affected by the 22Q4 pandemic, the performance recovery in 22H2 was lower than expected. 
The high demand due to soaring death rate since 22Q4 would be reflected in 23H1 results. Together with low base last year, strong performance rebound in 23H1 is worth expecting.
The reason behind short-term trade and long-term hold is different. But considering the Company has no obvious flaws in its long logic, every pullback can be a good buying opportunity.


Fu Shou Yuan (1448.HK) - 2022 Results Missed Expectations, but the Outlook Remains Positive